Elon Musk, the co-founder of Neuralink, has revealed that the highly anticipated human trial will begin at some point this year. This development comes after Neuralink received approval from the US government. Musk revealed that the initial trial will involve the implantation of the company’s technology in a patient who is tetraplegic or paraplegic.
Despite ongoing investigations regarding its animal experiments, Neuralink has received clearance from the US Food and Drug Administration (FDA) to proceed with its first-in-human clinical trial. This milestone approval marks a significant step for Neuralink, as it strives to revolutionize the field of brain-computer interfaces. The trial is aimed at evaluating the safety and efficacy of Neuralink’s technology in humans and holds potential promise for individuals suffering from paralysis-related conditions.
During his appearance at the VivaTech event in Paris, Elon Musk, who is also the CEO of Tesla, Twitter, and SpaceX, revealed the company’s plan to implant neural implants in a human recipient sometime this year. The announcement highlights Neuralink’s ambition to advance the field of brain-computer interfaces.
Musk shared this development with attendees at the event, stating that the procedure would be broadcasted via a webcast. The implantation, expected to be a significant milestone for Neuralink, signifies their progress towards achieving their goal of enhancing human capabilities through brain-chip technology. With Musk’s multi-faceted leadership across various groundbreaking ventures, the announcement has generated considerable anticipation regarding the potential implications of Neuralink’s advancements in neural implants.
Musk refrained from disclosing specific details about the forthcoming human trial and did not provide information regarding the number of patients involved or the trial’s duration.
Neuralink achieved a significant milestone in May when it received clearance from the US Food and Drug Administration (FDA) for its initial human clinical trial. The FDA’s approval marks an important step for the company, as it paves the way for Neuralink to explore the safety and efficacy of its groundbreaking technology in human subjects. The trial holds great potential for the future of brain-computer interfaces and has generated considerable interest among researchers, medical professionals, and the general public alike.
Nueralink’s Animal Trial Controversy:
Neuralink is currently facing an investigation in the United States concerning its handling of animal experiments. Former employees of Neuralink have come forward with allegations that the company conducted surgeries on monkeys, pigs, and sheep in a rushed and mishandled manner, leading to avoidable animal fatalities.
These experiments were reportedly conducted as part of Neuralink’s efforts to gather data in support of their application for human trials and were done under immense pressure from Musk.
The investigation into Neuralink’s practices sheds light on concerns regarding the company’s approach to animal experiments. Allegations of inadequate surgical procedures and unnecessary animal deaths have raised questions about the company’s adherence to proper protocols and ethical standards. As Neuralink strives to pioneer advancements in brain-computer interfaces, the investigation serves as a reminder of the importance of thorough and responsible research practices, particularly in the field of experimental medical technologies.
Experts say that Neuralink’s path to commercial use clearance may extend beyond a decade, despite demonstrating device safety in humans. The company also faces competition from other neurotech firms that have already implemented their devices.
Related:
- Elon Musk surprised by support for AI pause, calls for strong regulation
- Microsoft CEO Satya Nadella and Elon Musk Disagree on OpenAI Control
- Neuralink Receives Approval from FDA for Human Testing
(via)
